CompletedNCT02050854
Aripiprazole Levels in People Receiving Treatment for Bipolarity or Schizophrenia
About this title
Open-Label Observational Pilot Study to Evaluate the Pharmacokinetics of Aripiprazole in Subjects With Bipolar 1 Disorder or Schizophrenia
Read the official source — NCT02050854Observational studyAges 18–55United States
Understand this study
Who was this study for?
Listed age limits: 18 years to 55 years.
- Listed locations
- Garden Grove and 4 more locationsSee all locations and recruitment
Study information
Study start dateDecember 2013
- Recruitment status
- Completed
- Enrollment listed in the registry
- 47
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Sponsor type
- Pharmaceutical company
- Study type
- Observational
- Intervention type
- Interview / survey / observational
- Locations
- United States
- Age range
- From 18 Years to 55 Years
- Official registry ID
- NCT02050854
- Official title
Show the full official title
An Open-Label Observational Pilot Study to Evaluate the Pharmacokinetics of Aripiprazole in Subjects With Bipolar 1 Disorder or Schizophrenia Who Have a History of Suboptimal Adherence and Are Currently on Treatment With Oral Aripiprazole
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Garden Grove · Atlanta · Decatur
2 more locations
- Rockville
- Bellevue
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Otsuka Pharmaceutical Development & Commercialization, Inc., a pharmaceutical company.
Who was this study for?
Listed age limits: 18 years to 55 years.
